Eptinezumab-jjmr (Vyepti, Lundbeck) decreased mean monthly migraine days in adult patients in 2 phase 3 clinical trials.
Officials with the FDA have approved eptinezumab-jjmr (Vyepti, Lundbeck), the first intravenous (IV) treatment for the prevention of migraine in adults, according to a press release.
Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. The recommended dose is 100 mg every 3 months, but some patients may benefit from a 300-mg dose.
The approval is based on results from 2 phase 3 clinical trials: the PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine. In both studies, patients recieved either a placebo, eptinezumab-jjmr 100 mg, or eptinezumab-jjmr 300 mg. The primary endpoint was the change from baseline in mean monthly migraine day (MMD) over months 1 to 3. Patients were allowed to use concurrent acute migraine or headache medication, including migraine-specific medications, during the study.
Overall, the clinical trials demonstrated a treatment benefit over placebo for both doses of eptinezumab-jjmr as early as day 1 post-infusion. Additionally, the percentage of patients experiencing a migraine was lower for eptinezumab-jjmr than with placebo for most of the first 7 days. Among 2076 patients who received at least 1 dose of eptinezumab-jjmr, the most common adverse reactions were nasopharyngitis and hypersensitivity. In both trials, 1.9% of patients treated with eptinezumab-jjmr discontinued due to adverse reactions.
PROMISE-1 included a total of 665 patients who were randomized to 1 of the 3 treatment groups every 3 months for a 12-month period.
The results showed:
In PROMISE-2, a total of 1072 patents were randomized to receive a placebo, 100-mg eptinezumab-jjmr, or 300-mg eptinezumab-jjmr every 3 months for 6 months. According to the data:
“The PROMISE-2 data showed that many patients can achieve reduction in migraine days of at least 75% and experience a sustained migraine improvement through 6 months, which is clinically meaningful to both physicians and patients,” Dr Peter Goadsby, a professor of neurology at King’s College, London and the University of California, San Francisco, said in a statement. “Vyepti is a valuable addition for the treatment of migraine, which can help reduce the burden of this serious disease.”
Eptinezumab-jjmr will be available in April 2020, according to Lundbeck.
1. FDA approves Lundbeck’s VYEPTI (eptinezumab-jjmr)–the first and only intravenous preventive treatment for migraine [news release]. Lundbeck’s website. https://www.newsroom.lundbeckus.com/news-release/2020/fda-approves-lundbecks-vyepti-eptinezumab-jjmr-for-migraine. Accessed February 24, 2020.
FDA Approves Aprocitentan For Treatment of Uncontrolled High Blood Pressure
March 20th 2024Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.